Traws Pharma
TRAW
29 hedge funds and large institutions have $5.87M invested in Traws Pharma in 2020 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
232% more capital invested
Capital invested by funds: $1.77M → $5.87M (+$4.11M)
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
38% more funds holding
Funds holding: 21 → 29 (+8)
0.01% more ownership
Funds ownership: 0.01% → 0.02% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.55M |
| 2 |
Renaissance Technologies
New York
|
+$484K |
| 3 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
+$97K |
| 4 |
SAMH
Shanda Asset Management Holdings
Tortola,,
British Virgin Islands
|
+$78.2K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$52.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$441K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$55K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$7.95K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$7K |
| 5 |
CBFP
Cedar Brook Financial Partners
Cleveland,
Ohio
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Citadel Advisors
Miami,
Florida
| – | -$55K | -483 | Closed |
|
|
TSS
27
Two Sigma Securities
New York
| – | -$7K | -59 | Closed |
|
|
CBFP
28
Cedar Brook Financial Partners
Cleveland,
Ohio
| – | -$6K | -56 | Closed |
|
|
EWM
29
Edge Wealth Management
New York
| – | -$1K | -3 | Closed |
|
TRAW Hedge Fund Activity: Q2 2020 in Review
29 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q2 2020, worth a combined $5.87M — up 232% from $1.77M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TRAW positions and 4 closed out — a net gain of 9 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.55M. The largest seller was Susquehanna International Group, cutting an estimated $441K.
- 29 institutional investors held Traws Pharma (TRAW) as of Q2 2020, up from 21 in Q1 2020.
- Funds reported $5.87M of Traws Pharma stock for Q2 2020, up 232% quarter-over-quarter.
- 13 funds opened new Traws Pharma positions in Q2 2020 and 4 closed out, a net change of +9 holders.
- The largest Traws Pharma buyer in Q2 2020 was Vanguard Group, an estimated $1.55M added.
- The largest Traws Pharma seller in Q2 2020 was Susquehanna International Group, an estimated $441K sold.
Based on aggregated 13F filings for Q2 2020.